VTechWorks staff will be away for the Thanksgiving holiday starting at noon on Wednesday, November 23, through Friday, November 25, and will not be replying to requests during this time. Thank you for your patience.

Show simple item record

dc.contributor.authorMohamed, Mohamed F.en
dc.contributor.authorAbdelKhalek, Ahmeden
dc.contributor.authorSeleem, Mohamed N.en
dc.date.accessioned2020-09-21T16:15:31Zen
dc.date.available2020-09-21T16:15:31Zen
dc.date.issued2016-07-11en
dc.identifierARTN 29707 (Article number)en
dc.identifier.issn2045-2322en
dc.identifier.othersrep29707 (PII)en
dc.identifier.urihttp://hdl.handle.net/10919/100037en
dc.description.abstractMethicillin-resistant Staphylococcus aureus (MRSA) infections present a serious challenge because of the emergence of resistance to numerous conventional antibiotics. Due to their unique mode of action, antimicrobial peptides are novel alternatives to traditional antibiotics for tackling the issue of bacterial multidrug resistance. Herein, we investigated the antibacterial activity of two short novel peptides (WR12, a 12 residue peptide composed exclusively of arginine and tryptophan, and D-IK8, an eight residue β-sheet peptide) against multidrug resistant staphylococci. In vitro, both peptides exhibited good antibacterial activity against MRSA, vancomycin-resistant S. aureus, linezolid-resistant S. aureus, and methicillin-resistant S. epidermidis. WR12 and D-IK8 were able to eradicate persisters, MRSA in stationary growth phase, and showed significant clearance of intracellular MRSA in comparison to both vancomycin and linezolid. In vivo, topical WR12 and D-IK8 significantly reduced both the bacterial load and the levels of the pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in MRSA-infected skin lesions. Moreover, both peptides disrupted established in vitro biofilms of S. aureus and S. epidermidis significantly more so than traditional antimicrobials tested. Taken together, these results support the potential of WR12 and D-IK8 to be used as a topical antimicrobial agent for the treatment of staphylococcal skin infections.en
dc.format.extent14 page(s)en
dc.format.mediumElectronicen
dc.languageEnglishen
dc.publisherNature Publishing Groupen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectSOFT-TISSUE INFECTIONSen
dc.subjectPERSISTER CELLSen
dc.subjectANTIBIOTICSen
dc.subjectMECHANISMSen
dc.subjectDISEASEen
dc.subjectSKINen
dc.subjectEPIDERMIDISen
dc.subjectVANCOMYCINen
dc.subjectPEXIGANANen
dc.subjectPENETRATIONen
dc.subject.meshKeratinocytesen
dc.subject.meshHumansen
dc.subject.meshStaphylococcus epidermidisen
dc.subject.meshStaphylococcal Skin Infectionsen
dc.subject.meshAntimicrobial Cationic Peptidesen
dc.subject.meshAnti-Bacterial Agentsen
dc.subject.meshMethicillin-Resistant Staphylococcus aureusen
dc.titleEvaluation of short synthetic antimicrobial peptides for treatment of drug-resistant and intracellular Staphylococcus aureusen
dc.typeArticle - Refereeden
dc.date.updated2020-09-21T16:15:27Zen
dc.description.versionPublished (Publication status)en
dc.title.serialScientific Reportsen
dc.identifier.doihttps://doi.org/10.1038/srep29707en
dc.type.otherArticleen
dc.type.otherJournalen
dc.identifier.volume6en
dc.identifier.issue1en
dc.identifier.orcidSeleem, Mohamed [0000-0003-0939-0458]en
dc.identifier.pmid27405275 (pubmed)en
dcterms.dateAccepted2016-06-21en
dc.identifier.eissn2045-2322en
pubs.organisational-group/Virginia Tech/Veterinary Medicineen
pubs.organisational-group/Virginia Tech/Faculty of Health Sciencesen
pubs.organisational-group/Virginia Tech/All T&R Facultyen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/Biomedical Sciences and Pathobiologyen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/CVM T&R Facultyen
pubs.organisational-group/Virginia Techen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution 4.0 International
License: Creative Commons Attribution 4.0 International